Suppr超能文献

去势抵抗性前列腺癌的主要病因。

Leading causes of castration-resistant prostate cancer.

作者信息

Lu Mingqian, Lu Hongda, Kong Qingzhi

机构信息

Clinical Medical College, Hubei University of Chinese Medicine, Wuhan 430061, Hubei province, China.

出版信息

Expert Rev Anticancer Ther. 2015 Apr;15(4):425-32. doi: 10.1586/14737140.2015.1007957. Epub 2015 Feb 3.

Abstract

Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.

摘要

前列腺癌(PCa)是男性癌症相关死亡的第二大主要原因。雄激素受体在PCa的发生和发展中起关键作用。目前,雄激素剥夺疗法因其有效抑制雄激素受体信号传导而成为PCa患者的标准治疗方法。尽管雄激素剥夺疗法在缩小肿瘤大小方面显示出初步疗效,但最终无法治愈晚期PCa,这是由去势抵抗的发生所决定的。在本综述中,我们总结了导致去势抵抗性PCa的广泛接受的机制,并讨论了潜在的治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验